ANVISA Guide
ANVISA regulatory translation requirements.
A technical guide to the linguistic, formatting, and certification rules Brazil's Agência Nacional de Vigilância Sanitária applies to clinical trial translation for drug marketing authorizations and Phase III submissions — and why general-purpose AI translation drives avoidable queries in first-cycle review.
Published July 2026
The context
Brazil reads every filing in Portuguese, and reads it strictly.
ANVISA is the federal regulator for medicines, devices, biologics, and clinical research in Brazil. Every dossier submitted to ANVISA — from the Dossiê de Desenvolvimento Clínico de Medicamento (DDCM) that authorizes a Phase III trial, to the registration dossier for a new marketing authorization — is reviewed in Brazilian Portuguese. Source-language documents are accepted only when accompanied by a translation that meets Brazil's formal requirements. Anything less generates an exigência, and each exigência resets the review clock.
For sponsors targeting the keyword that drives most of this traffic — clinical trial translation — Brazil is where the strictest interpretation lives. What passes review in Mexico or Argentina will still fail here if the certification chain is wrong or the terminology drifts from ANVISA's own published glossaries.
What ANVISA actually requires
Four requirement families you cannot skip.
Sworn (juramentada) translation for legal instruments.
Contracts, powers of attorney, corporate authorizations, and any document that will produce legal effect in Brazil must be translated by a tradutor público juramentado registered with a Brazilian Junta Comercial. This is not optional and cannot be satisfied by an in-house or agency certification. Missing sworn translations are one of the most common structural rejections in first-cycle review of marketing authorization dossiers.
Technical translation aligned to ANVISA terminology.
Protocols, Investigator's Brochures, IFUs, and product monographs are technical translations. ANVISA maintains published glossaries (Vocabulário Controlado, RDC-referenced terminology) for drug classes, adverse events, and study design terms. Deviations from the controlled vocabulary — even accurate synonyms — trigger clarifying queries because the reviewer cannot map your term to the regulated category.
Patient-facing materials read by CEP/CONEP.
The Termo de Consentimento Livre e Esclarecido (TCLE) and any recruitment material are reviewed by the Comitê de Ética em Pesquisa at each site and, for multicenter or specific-topic trials, by the national CONEP. Reading level, risk-statement phrasing, and rights language are held to a stricter standard than the underlying protocol. A TCLE that reads as a literal machine translation of the English consent will be sent back for rewrite.
Formatting, pagination, and bilingual submission structure.
ANVISA specifies dossier structure in RDC and Instrução Normativa documents. Translated files must preserve the source document's numbering, cross-references, and appendix order so the reviewer can compare line-by-line. Standalone translations without the paired source, or PDFs where pagination has drifted, are frequently returned before technical review even begins.
Why general-purpose AI translation fails here
The rejection pattern is predictable, and it is expensive.
General-purpose large language models translate for fluency. ANVISA reviews for fidelity to a controlled vocabulary and to a specific document structure. The two objectives diverge in three predictable places: adverse event terms rendered as natural Portuguese instead of the MedDRA-aligned form ANVISA expects; risk statements in the TCLE softened into more readable prose that loses the regulatory weight of the source; and unit conventions, dosing intervals, and route-of-administration phrases silently normalized to a variant Brazil does not accept.
Each of these produces an exigência, and each exigência costs weeks. For a Phase III program with an active enrollment target or a marketing authorization on the commercial calendar, weeks are not a rounding error — they are the difference between hitting a launch date and missing it.
For a fuller comparison of the failure modes, read AI vs. medical review accuracy or the wider guide on translation impact across Latin America.
How we cover this
The First-Pass Acceptance Program.
Our clinical trial translation service pairs AI-assisted translation with medical review by clinicians who read ANVISA guidance for a living, then routes legal instruments to registered tradutores públicos juramentados before the dossier is assembled. The output is a Portuguese submission package aligned to ANVISA's controlled vocabulary and formatting rules — not a fluent paraphrase.
We back it with a written SLA: zero critical errors on delivery, or we re-issue at no cost and credit $2,500 per business day of delay. For ANVISA submissions, that credit is not symbolic — it is priced against the actual commercial cost of a delayed marketing authorization or a late Phase III start.
Related resources
Continue reading across the LatAm regulatory stack.
Clinical Trial Translation Services hub
The Amavita overview of LatAm regulator coverage, MD-led review, and the First-Pass Acceptance SLA.
Read more →COFEPRIS translation requirements (Mexico)
Spanish submission rules for COFEPRIS clinical trials, registrations, and labeling.
Read more →INVIMA translation requirements (Colombia)
Colombian Spanish submission rules, certified translator requirements, and common auto de requerimiento.
Read more →ANMAT translation requirements (Argentina)
Disposición 6677/10, traductor público matriculado, and rioplatense Spanish for the informed consent.
Read more →LatAm market access impact
How translation quality shapes the speed of market clearance and audit success across Latin America.
Read more →AI vs. medical review accuracy
Where general-purpose AI translation fails on Phase III documentation and how MD-led review closes the gap.
Read more →Ready to move a Brazil program? Start an ANVISA pilot with Amavita →
Next step
Move a Brazil program through the workflow.
Tell us about an ANVISA submission or Phase III program on your calendar. Our team will reach out within 2 business days with a scoped pilot proposal.